Table 6.
Weight and body mass index (BMI) at baseline and changes during study period*
| Quetiapine group (n=89) | Placebo group (n=89) | df | P value | |
|---|---|---|---|---|
| All participants | ||||
| Mean (SD) weight (kg): | ||||
| Baseline | 66.03 (14.47) | 66.28 (15.10) | 176 | 0.91 |
| End of study | 65.28 (14.14) | 63.36 (14.32) | 175 | 0.37 |
| Mean (SD) BMI: | ||||
| Baseline | 24.46 (4.75) | 24.49 (4.95) | 176 | 0.97 |
| End of study | 24.19 (4.75) | 23.41 (4.64) | 175 | 0.27 |
| No (%) BMI ≥23: | ||||
| Baseline | 49 (55) | 53 (60) | 1 | 0.65 |
| End of study | 44 (49) | 39 (44) | 1 | 0.60 |
| No (%) weight gain ≥7% | 9 (10) | 9 (10) | 1 | >0.99 |
| Mean (SD) weight change (kg) | −0.75 (4.65) | −3.08 (8.22) | NA | |
| Mean (SD) BMI change | −0.26 (1.72) | −1.14 (3.09) | NA | |
| BMI <23 at baseline | (n=40) | (n=35) | ||
| Mean (SD) weight change (kg) | −0.01 (2.99) | −0.83 (5.02) | NA | |
| Mean (SD) BMI change | −0.002 (1.12) | −0.32 (1.79) | NA | |
| No (%) BMI ≥23 at end of study | 3 (8) | 1 (3) | NA | |
| BMI ≥23 at baseline | (n=49) | (n=53) | ||
| Mean (SD) weight change (kg) | −1.36 (5.62) | −4.56 (9.54) | NA | |
| Mean (SD) BMI change | −0.48 (2.07) | −1.68 (3.62) | NA | |
| No (%) BMI <23 at end of study | 8 (16) | 15 (28) | NA | |
| Previous typical antipsychotics | (n=41) | (n=44) | ||
| Mean (SD) weight change (kg) | −0.21 (5.25) | −1.53 (6.92) | NA | |
| Mean (SD) BMI change | −0.07 (1.92) | −0.57 (2.57) | NA | |
| Previous atypical antipsychotics | (n=48) | (n=44) | ||
| Mean (SD) weight change (kg) | −1.22 (4.07) | −4.62 (9.16) | NA | |
| Mean (SD) BMI change | −0.43 (1.53) | −1.71 (3.64) | NA | |
NA=not applicable.
*Descriptive and initial analyses used t tests for continuous variables and χ2 tests for categorical variables. Weight data from 178 patients at baseline and 177 patients at end of study.